Antibody based immunotherapy for multiple myeloma: it’s about time

References

• Pratt G, Goodyear O, Moss P. Immunodeficiency and immunotherapy in multiple myeloma. Br J Haematol 2007; 138: 563–579.
   PubMed Web of Science ®Google Scholar
• Danylesko I, Beider K, Shimoni A, et al. Novel strategies for immunotherapy in multiple myeloma: previous experience and future directions. Clin Dev Immunol 2012; 2012: 753407.
   PubMedGoogle Scholar
• Chillemi A, Zaccarello G, Quarona V, et al. CD38 and bone marrow microenvironment. Front Biosci (Landmark Ed) 2014; 19: 152–162.
   PubMed Web of Science ®Google Scholar
• Overdijk MB, Verploegen S, Bögels M, et al. Antibody-mediated phagocytosis contributes to the anti-tumor activity of the therapeutic antibody daratumumab in lymphoma and multiple myeloma. mAbs 2015; 7: 311–321.
   PubMed Web of Science ®Google Scholar
• Lokhorst HM, Plesner T, Laubach JP, et al. Targeting CD38 with daratumumab monotherapy in multiple myeloma. N Engl J Med 2015; 373: 1207–1219
   PubMed Web of Science ®Google Scholar
• Lonial S, Weiss BM, Usmani SZ, et al. Phase II study of Daratumumab (DARA) monotherapy in patients with more than 3 lines of prior therapy or double refractory multiple myeloma. J Clin Oncol 2015; 33(Suppl):asbtract LBA8512.
   PubMed Web of Science ®Google Scholar
• Nijhof IS, van Bueren JJL, van Kessel B, et al. Daratumumab-mediated lysis of primary multiple myeloma cells is enhanced in combination with the human anti-KIR antibody IPH2102 and lenalidomide. Haematologica 2015; 100: 263–268.
   PubMed Web of Science ®Google Scholar
• Deckert J, Wetzel MC, Bartle LM, et al. SAR650984, a novel humanized CD38-targeting antibody, demonstrates potent antitumor activity in models of multiple myeloma and other CD38 + hematologic malignancies. Clin Cancer Res 2014; 20: 4574–4583.
   PubMed Web of Science ®Google Scholar
• Martin TG, Hsu K, Strickland SA, et al. A phase I trial of SAR650984, a CD38 monoclonal antibody, in relapsed or refractory multiple myeloma. J Clin Oncol 2014; 32:8532.
   Web of Science ®Google Scholar
• Martin TG, Baz R, Benson DM, et al. A Phase Ib Dose Escalation Trial of SAR650984 (Anti-CD-38 mAb) in combination with lenalidomide and dexamethasone in relapsed/refractory multiple myeloma. Blood 2014; 124(21): Abstract 83.
   Google Scholar
• Veillette A, Guo H. CS1, a SLAM family receptor involved in immune regulation, is a therapeutic target in multiple myeloma. Crit Rev Oncol Hematol 2013; 88: 168–177.
   PubMed Web of Science ®Google Scholar
• Collins SM, Bakan CE, Swartzel GD, et al. Elotuzumab directly enhances NK cell cytotoxicity against myeloma via CS1 ligation: evidence for augmented NK cell function complementing ADCC. Cancer Immunology, Immunotherapy 2013; 62: 1841–1849.
   PubMed Web of Science ®Google Scholar
• Zonder JA, Mohrbacher AF, Singhal S, et al. A phase 1, multicenter, open-label, dose escalation study of elotuzumab in patients with advanced multiple myeloma. Blood 2012; 120: 552–559.
   PubMed Web of Science ®Google Scholar
• Richardson PG, et al. Final results for the 1703 phase 1b/2 study of elotuzumab in combination with lenalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma. Blood 2014; 124:(21): 302.
   Web of Science ®Google Scholar
• Lonial S, Dimopoulos M, Palumbo A, et al. Elotuzumab therapy for relapsed or refractory multiple myeloma. N Engl J Med 2015; 373: 621–631.
   PubMed Web of Science ®Google Scholar
• Terpos E, Kanellias N, Giannopoulos K. Biology and management of myeloma-related bone disease. Acta Haematol Polonica 2014; 45: 107–121.
   Google Scholar
• Henry DH, Costa L, Goldwasser F, et al. Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. J Clin Oncol 2011; 29: 1125–1132.
   PubMed Web of Science ®Google Scholar
• Fulciniti M, Tassone P, Hideshima T, et al. Anti-DKK1 mAb (BHQ880) as a potential therapeutic agent for multiple myeloma. Blood 2009; 114: 371–379.
   PubMed Web of Science ®Google Scholar
• Padmanabhan S, Beck JT, Kelly KR, et al. A phase I/II study of BHQ880, a novel osteoblast activating, anti-DKK1 human monoclonal antibody, in relapsed and refractory multiple myeloma (MM) patients treated with zoledronic acid (Zol) and anti-myeloma therapy (MM Tx). Blood 2009; 114: 312–313.
   Web of Science ®Google Scholar
• Chang Q, Daly L, Bromberg J. The IL-6 feed-forward loop: a driver of tumorigenesis. Semin Immunol 2014; 26: 48–53.
   PubMed Web of Science ®Google Scholar
• Markham A, Patel T. Siltuximab: first global approval. Drugs 2014; 74: 1147–1152.
   PubMed Web of Science ®Google Scholar
• Kurzrock R, Voorhees PM, Casper C, et al. A phase I, open-label study of siltuximab, an anti-IL-6 monoclonal antibody, in patients with B-cell non-Hodgkin lymphoma, multiple myeloma, or Castleman disease. Clin Cancer Res 2013; 19: 3659–3670.
   PubMed Web of Science ®Google Scholar
• Orlowski RZ, Gercheva L, Williiams C, et al. A phase 2, randomized, double-blind, placebo-controlled study of siltuximab (anti-IL-6 mAb) and bortezomib versus bortezomib alone in patients with relapsed or refractory multiple myeloma. Am J Hematol 2015; 90: 42–49.
   PubMed Web of Science ®Google Scholar
• San-Miguel J, Bladé J, Shpilberg O, et al. Phase 2 randomized study of bortezomib-melphalan-prednisone with or without siltuximab (anti-IL-6) in multiple myeloma. Blood 2014; 123: 4136–4142.
   PubMed Web of Science ®Google Scholar
• Allegra A, Penna G, Alonci A, et al. Monoclonal antibodies: Potential new therapeutic treatment against multiple myeloma. Eur J Haematol 2013; 90: 441–468.
   PubMed Web of Science ®Google Scholar
• Scagliotti GV, Bondarenko I, Blackhall F, et al. Randomized, phase III trial of figitumumab in combination with erlotinib versus erlotinib alone in patients with nonadenocarcinoma nonsmall-cell lung cancer. Ann Oncol 2015; 26: 497–504.
   PubMed Web of Science ®Google Scholar
• West H. The failure of figitumumab: the danger of taking shortcuts in drug development. Ann Oncol 2015; 26: 447–448.
   PubMed Web of Science ®Google Scholar
• Franklin R, Samson MK, Fraile RJ, et al. A phase I-II study of maytansine utilizing a weekly schedule. Cancer 1980; 46: 1104–1108.
   PubMed Web of Science ®Google Scholar
• Kim SU, Tomonaga M, Ghetti B. Neurofibrillary degeneration in cultured adult mouse neurons induced by maytansine. Acta Neuropathol 1980; 52: 161–164.
   PubMed Web of Science ®Google Scholar
• Ikeda H, Hideshima T, Fulciniti M, et al. The monoclonal antibody nBT062 conjugated to cytotoxic Maytansinoids has selective cytotoxicity against CD138-positive multiple myeloma cells in vitro and in vivo. Clin Cancer Res 2009; 15: 4028–4037.
   PubMed Web of Science ®Google Scholar
• Kelly KR, Chanan-Khan A, Heffner LT, et al. Indatuximab Ravtansine (BT062) in combination with Lenalidomide and low-dose Dexamethasone in patients with relapsed and/or refractory multiple myeloma: clinical activity in patients already exposed to Lenalidomide and Bortezomib. Blood 2014; 124.
   Google Scholar
• Chanan-Khan A, Wolf J, Garcia J, et al. Efficacy analysis from a Phase I Study of Lorvotuzumab Mertansine (IMGN901), used as Monotherapy, in patients with heavily pre-treated CD56-Positive Multiple Myeloma–A preliminary efficacy analysis. Blood 2010; 116: 819–819.
   PubMed Web of Science ®Google Scholar
• Berdeja JG. Lorvotuzumab mertansine: antibody-drug-conjugate for CD56 + multiple myeloma. Front Biosci (Landmark Ed) 2014; 19: 163–170.
   PubMed Web of Science ®Google Scholar
• Spencer A, Walker P, Asvadi P, et al. A phase I study of the anti-appa monoclonal antibody, MDX-1097, in previously treated multiple myeloma patients. J Clin Oncol 2010; 28: 8143.
   Google Scholar
• Korde N, Carlsten M, Lee M-J, et al. A phase II trial of pan-KIR2D blockade with IPH2101 in smoldering multiple myeloma. Haematologica 2014; 99: e81–83.
   PubMed Web of Science ®Google Scholar
• Trudel S, Wei E, Hua Z, et al. Targeting FGFR3 in t(4;14) mutiple myeloma: pre-clinical studies of PRO-001, a novel anti-FGFR3 neutralizing antibody. Blood 2004; 104: 680A.
   Web of Science ®Google Scholar